Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats.
Identifieur interne : 000377 ( Main/Exploration ); précédent : 000376; suivant : 000378Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats.
Auteurs : Roberto Di Maio [Italie] ; Jason R. Cannon [États-Unis] ; J Timothy Greenamyre [États-Unis]Source :
- Neurobiology of disease [ 1095-953X ] ; 2015.
Descripteurs français
- KwdFr :
- Agonistes des récepteurs de cannabinoïdes (pharmacologie), Animaux, Benzoxazines (pharmacologie), Hippocampe (), Hippocampe (métabolisme), Maladie chronique (), Modèles animaux de maladie humaine, Morpholines (pharmacologie), Mâle, Naphtalènes (pharmacologie), Rat Sprague-Dawley, Rats, Épilepsie (), État de mal épileptique (), État de mal épileptique (traitement médicamenteux).
- MESH :
- métabolisme : Hippocampe.
- pharmacologie : Agonistes des récepteurs de cannabinoïdes, Benzoxazines, Morpholines, Naphtalènes.
- traitement médicamenteux : État de mal épileptique.
- Animaux, Hippocampe, Maladie chronique, Modèles animaux de maladie humaine, Mâle, Rat Sprague-Dawley, Rats, Épilepsie, État de mal épileptique.
English descriptors
- KwdEn :
- Animals, Benzoxazines (pharmacology), Cannabinoid Receptor Agonists (pharmacology), Chronic Disease (prevention & control), Disease Models, Animal, Epilepsy (prevention & control), Hippocampus (drug effects), Hippocampus (metabolism), Male, Morpholines (pharmacology), Naphthalenes (pharmacology), Rats, Rats, Sprague-Dawley, Status Epilepticus (chemically induced), Status Epilepticus (drug therapy).
- MESH :
- chemical , pharmacology : Benzoxazines, Cannabinoid Receptor Agonists, Morpholines, Naphthalenes.
- chemically induced : Status Epilepticus.
- drug effects : Hippocampus.
- drug therapy : Status Epilepticus.
- metabolism : Hippocampus.
- prevention & control : Chronic Disease, Epilepsy.
- Animals, Disease Models, Animal, Male, Rats, Rats, Sprague-Dawley.
Abstract
Repeated seizures are often associated with development of refractory chronic epilepsy, the most common form of which is temporal lobe epilepsy. G-protein-coupled cannabinoid receptors (CB1 and CB2 receptors) regulate neuronal excitability and have been shown to mediate acute anticonvulsant effects of cannabinoids in animal models. However, the potential of cannabinoids to prevent chronic neuronal damage and development of epilepsy remains unexplored. We hypothesized that treatment with a CB receptor agonist after an episode of status epilepticus--but before development of spontaneous recurrent seizures--might prevent the development of functional changes that lead to chronic epilepsy. Using the rat pilocarpine model, a therapeutic approach was simulated by administering the CB agonist, WIN 55,212-2 after an episode of status epilepticus. Epileptic behavior was monitored during development of spontaneous recurrent seizures for up to 6 months. Histology, neurochemistry, redox status and NMDA receptor subunit expression were assessed at 6 months after pilocarpine-induced seizures. Sub-acute treatment with WIN 55,212-2 (for 15 days starting 24h after PILO injection) dramatically attenuated the severity, duration and frequency of spontaneous recurrent seizures. Further, in contrast to vehicle-treated animals, hippocampi from WIN 55,212-2-treated animals showed: normal thiol redox state, normal NR2A and NR2B subunit expression, preservation of GABAergic neurons and prevention of abnormal proliferation of GABAergic progenitors. This study shows for the first time that, after a known inciting event, treatment with a compound targeting CB receptors has the potential to prevent the epileptogenic events that result in chronic epileptic damage.
DOI: 10.1016/j.nbd.2014.10.018
PubMed: 25447228
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000828
- to stream PubMed, to step Curation: 000828
- to stream PubMed, to step Checkpoint: 000828
- to stream Ncbi, to step Merge: 004099
- to stream Ncbi, to step Curation: 004099
- to stream Ncbi, to step Checkpoint: 004099
- to stream Main, to step Merge: 000377
- to stream Main, to step Curation: 000377
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats.</title><author><name sortKey="Di Maio, Roberto" sort="Di Maio, Roberto" uniqKey="Di Maio R" first="Roberto" last="Di Maio">Roberto Di Maio</name><affiliation wicri:level="4"><nlm:affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh, USA; RiMED Foundation, Palermo, Italy. Electronic address: rdimaio@hs.pitt.edu.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh, USA; RiMED Foundation, Palermo</wicri:regionArea><orgName type="university">Université de Pittsburgh</orgName><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Cannon, Jason R" sort="Cannon, Jason R" uniqKey="Cannon J" first="Jason R" last="Cannon">Jason R. Cannon</name><affiliation wicri:level="2"><nlm:affiliation>School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J Timothy" last="Greenamyre">J Timothy Greenamyre</name><affiliation wicri:level="4"><nlm:affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh</wicri:regionArea><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25447228</idno><idno type="pmid">25447228</idno><idno type="doi">10.1016/j.nbd.2014.10.018</idno><idno type="wicri:Area/PubMed/Corpus">000828</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000828</idno><idno type="wicri:Area/PubMed/Curation">000828</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000828</idno><idno type="wicri:Area/PubMed/Checkpoint">000828</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000828</idno><idno type="wicri:Area/Ncbi/Merge">004099</idno><idno type="wicri:Area/Ncbi/Curation">004099</idno><idno type="wicri:Area/Ncbi/Checkpoint">004099</idno><idno type="wicri:Area/Main/Merge">000377</idno><idno type="wicri:Area/Main/Curation">000377</idno><idno type="wicri:Area/Main/Exploration">000377</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats.</title><author><name sortKey="Di Maio, Roberto" sort="Di Maio, Roberto" uniqKey="Di Maio R" first="Roberto" last="Di Maio">Roberto Di Maio</name><affiliation wicri:level="4"><nlm:affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh, USA; RiMED Foundation, Palermo, Italy. Electronic address: rdimaio@hs.pitt.edu.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh, USA; RiMED Foundation, Palermo</wicri:regionArea><orgName type="university">Université de Pittsburgh</orgName><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Cannon, Jason R" sort="Cannon, Jason R" uniqKey="Cannon J" first="Jason R" last="Cannon">Jason R. Cannon</name><affiliation wicri:level="2"><nlm:affiliation>School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J Timothy" last="Greenamyre">J Timothy Greenamyre</name><affiliation wicri:level="4"><nlm:affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh</wicri:regionArea><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="eISSN">1095-953X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Benzoxazines (pharmacology)</term><term>Cannabinoid Receptor Agonists (pharmacology)</term><term>Chronic Disease (prevention & control)</term><term>Disease Models, Animal</term><term>Epilepsy (prevention & control)</term><term>Hippocampus (drug effects)</term><term>Hippocampus (metabolism)</term><term>Male</term><term>Morpholines (pharmacology)</term><term>Naphthalenes (pharmacology)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Status Epilepticus (chemically induced)</term><term>Status Epilepticus (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agonistes des récepteurs de cannabinoïdes (pharmacologie)</term><term>Animaux</term><term>Benzoxazines (pharmacologie)</term><term>Hippocampe ()</term><term>Hippocampe (métabolisme)</term><term>Maladie chronique ()</term><term>Modèles animaux de maladie humaine</term><term>Morpholines (pharmacologie)</term><term>Mâle</term><term>Naphtalènes (pharmacologie)</term><term>Rat Sprague-Dawley</term><term>Rats</term><term>Épilepsie ()</term><term>État de mal épileptique ()</term><term>État de mal épileptique (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzoxazines</term><term>Cannabinoid Receptor Agonists</term><term>Morpholines</term><term>Naphthalenes</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Status Epilepticus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hippocampus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Status Epilepticus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Hippocampus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hippocampe</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agonistes des récepteurs de cannabinoïdes</term><term>Benzoxazines</term><term>Morpholines</term><term>Naphtalènes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Chronic Disease</term><term>Epilepsy</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>État de mal épileptique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Hippocampe</term><term>Maladie chronique</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Rat Sprague-Dawley</term><term>Rats</term><term>Épilepsie</term><term>État de mal épileptique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Repeated seizures are often associated with development of refractory chronic epilepsy, the most common form of which is temporal lobe epilepsy. G-protein-coupled cannabinoid receptors (CB1 and CB2 receptors) regulate neuronal excitability and have been shown to mediate acute anticonvulsant effects of cannabinoids in animal models. However, the potential of cannabinoids to prevent chronic neuronal damage and development of epilepsy remains unexplored. We hypothesized that treatment with a CB receptor agonist after an episode of status epilepticus--but before development of spontaneous recurrent seizures--might prevent the development of functional changes that lead to chronic epilepsy. Using the rat pilocarpine model, a therapeutic approach was simulated by administering the CB agonist, WIN 55,212-2 after an episode of status epilepticus. Epileptic behavior was monitored during development of spontaneous recurrent seizures for up to 6 months. Histology, neurochemistry, redox status and NMDA receptor subunit expression were assessed at 6 months after pilocarpine-induced seizures. Sub-acute treatment with WIN 55,212-2 (for 15 days starting 24h after PILO injection) dramatically attenuated the severity, duration and frequency of spontaneous recurrent seizures. Further, in contrast to vehicle-treated animals, hippocampi from WIN 55,212-2-treated animals showed: normal thiol redox state, normal NR2A and NR2B subunit expression, preservation of GABAergic neurons and prevention of abnormal proliferation of GABAergic progenitors. This study shows for the first time that, after a known inciting event, treatment with a compound targeting CB receptors has the potential to prevent the epileptogenic events that result in chronic epileptic damage.</div></front></TEI><affiliations><list><country><li>Italie</li><li>États-Unis</li></country><region><li>Indiana</li><li>Pennsylvanie</li></region><settlement><li>Pittsburgh</li></settlement><orgName><li>Université de Pittsburgh</li></orgName></list><tree><country name="Italie"><region name="Pennsylvanie"><name sortKey="Di Maio, Roberto" sort="Di Maio, Roberto" uniqKey="Di Maio R" first="Roberto" last="Di Maio">Roberto Di Maio</name></region></country><country name="États-Unis"><region name="Indiana"><name sortKey="Cannon, Jason R" sort="Cannon, Jason R" uniqKey="Cannon J" first="Jason R" last="Cannon">Jason R. Cannon</name></region><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J Timothy" last="Greenamyre">J Timothy Greenamyre</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000377 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000377 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25447228
|texte= Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25447228" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |